Drug
Mgcd0103 And Azacitidine
Mgcd0103 And Azacitidine: highest development phase Phase 2, developed by Mirati Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Mirati Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| MGCD0103 and Azacitidine NCT00543582 | Phase 2 | Hodgkin Lymphoma |
Latest
No recent events.
Follow Mgcd0103 And Azacitidine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.